Efficacy of Xiaokeqing granules and lifestyle intervention in treating prediabetes mellitus considering metabolomic biomarkers: A randomised controlled trial

doi:10.4239/wjd.v16.i7.105219

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (807)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-9) series.

Item

Count

PDF

HTML

461

Figures (1-5)

Tables (1-9)

Sum=673

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=83

Jul 15, 2025 (publication date) through Aug 13, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Diabetes. Jul 15, 2025; 16(7): 105219
Published online Jul 15, 2025. doi: 10.4239/wjd.v16.i7.105219

Full Size Figure Download Figure

Figure 5 Network pharmacology and molecular docking. A: Key targets; B: Molecules docking heatmap of Xiaokeqing granule constituents absorbed in the blood, core metabolomics biomarkers and key targets; C: Molecular docking visualization of groenlandicine and HTR2C; D: Molecular docking visualization of 5-hydroxy-L-tryptophan and SLC6A4.

Citation: Zhao JD, Guo MZ, Zhang Y, Zhu SH, Wang YT, Zhang YP, Liu X, Cheng S, Wang F, Xu Q, Ruan NB, Fang ZH. Efficacy of Xiaokeqing granules and lifestyle intervention in treating prediabetes mellitus considering metabolomic biomarkers: A randomised controlled trial. World J Diabetes 2025; 16(7): 105219
URL: https://www.wjgnet.com/1948-9358/full/v16/i7/105219.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i7.105219